Search

Meet Michaela Gruber, our December volunteer of the month

Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.

Read more

Meet Michaela Gruber, our December volunteer of the month

Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.

Read more

Meet Ton Hagenbeek, our May volunteer of the month

Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.

Read more

Meet Ton Hagenbeek, our May volunteer of the month

Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.

Read more

Meet Fabienne Lucas, our January Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Meet Fabienne Lucas, our January Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Highlights of the EHA-EMA Joint Symposium on RWE

The fourth EHA-EMA Joint Symposium at EHA2024 brought together investigators, regulators and patients to discuss the use of real world evidence (RWE) in the evaluation of new drugs.

Read more

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…

Read more